Back to Results
First PageMeta Content
Lactams / Piperazines / Pyrazolopyrimidines / Pyrrolidines / CGMP-specific phosphodiesterase type 5 / Sildenafil / Tadalafil / Erectile dysfunction / Avanafil / Organic chemistry / Chemistry / PDE5 inhibitors


Karessa Pharma Holding AB (publ) Company Description for listing on Nasdaq Stockholm First North February 2015
Add to Reading List

Document Date: 2015-02-18 05:34:46

Open Document

File Size: 1.014,34 KB

Share Result on Facebook

City

Stockholm / /

Company

Directors 4 Karessa Pharma Holding AB / Remium Nordic AB / Legal / Vardenalfil Eli Lilly & Co / Eli Lilly Since 2003 / Pfizer Inc / NASDAQ OMX Stockholm AB / Bayer AG / Nasdaq Stockholm First North Pfizer Pfizer / Euroclear Sweden AB / Karessa Pharma Holding AB / Sildenafil 8 Karessa Pharma Holding AB / Eli Lilly & Co / /

Continent

Asia / North America / Europe / /

Country

Switzerland / Germany / Italy / New Zealand / France / Japan / Russia / United States / Brazil / Canada / United Kingdom / China / Spain / India / /

Currency

GBP / SEK / USD / EUR / /

Event

Product Release / FDA Phase / /

IndustryTerm

pharmaceutical / medicinal products / food / medicinal product / treatment of erectile dysfunction / /

MedicalCondition

muscular aches / headache / obesity / CIN / Erectile Dysfunction / nasal congestion / diabetes / cardiovascular disease / single biggest factor underlying erectile dysfunction / pain / diseases / pains / high blood pressure / /

MedicalTreatment

herbal remedies / /

MusicAlbum

in Europe / Asia / /

Organization

United Nations / European Union / Swedish Financial Supervisory Authority / /

Person

KARE ISIN / /

Position

certified adviser / CEO / medicinal Torbjörn Kemper CEO / Annual General / /

Product

Alprostadil / Levitra / Testosterone / Faster / Cialis / Caverject / Viagra / Company / /

Region

Northern Europe / Latin America / /

Technology

drug delivery / drug development / /

SocialTag